U.S. screening recommendations now include men with high-risk germline mutations (such as BRCA2 or Lynch syndrome MMR genes) or high-risk ancestry (e.g., African or Ashkenazi Jewish heritage) within the “high-risk” category for earlier PSA-based screening, typically in the 40s [15,16]. The gene discussed is MRC1; the disease is Lynch syndrome.